{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"37","upperLimit":"137","value":"120"},{"groupId":"OG001","lowerLimit":"27","upperLimit":"137","value":"89"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"9"}],"units":"Participants"}],"description":"Disease-free survival is defined as participants who are still alive and without disease at study completion. Study completion was either death or completion of all protocol-specified activities, whichever came first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive veliparib PO BID on days 1-21 and topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 3-7. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm A (Veliparib, Topotecan Hydrochloride, Carboplatin)"},{"description":"Patients receive topotecan hydrochloride IV continuously over 24 hours and carboplatin IV continuously over 24 hours on days 1-5. Treatment repeats every 28-63 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Arm B (Topotecan Hydrochloride, Carboplatin)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Up to 7 months","title":"Duration of Disease-free Survival","type":"SECONDARY","unitOfMeasure":"days"}